BPI-1178
As of the edition of 20 October 2026, BPI-1178 is a drug known only by a code name: of no established status; acts on CDK4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Code name only
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CDK4 | Cyclin-dependent kinase 4 | P11802 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Beta Pharma | Lead sponsor of trials | 2020 to now |